On February 18, 2026, Organigram Global Inc., a leading licensed producer of cannabis, announced that it has entered into a definitive purchase agreement to acquire all issued and outstanding shares of Berlin-based Sanity Group GmbH not currently owned by Organigram. Total upfront consideration is €113.4 million (C$183.7 million), consisting of €80 million (C$129.6 million) in cash and €33.4 million (C$54.1 million) in Organigram shares. In addition, the vendors are entitled to receive earnout consideration of up to €113.8 million (C$184.3 million), based on Sanity's financial performance for the 12-month period following closing, bringing the total potential transaction value to up to approximately €250 million (C$405 million). The upfront consideration shares are expected to be priced at C$3.00 per Organigram share, representing a 71 percent premium to the C$1.75 closing price on the TSX on February 17, 2026. The acquisition is expected to be financed by a combination of cash on hand, proceeds from a new senior secured credit facility of up to C$60 million arranged by ATB Financial, and an expected C$65.2 million equity investment by British American Tobacco plc (BAT) through its subsidiary BT DE Investments Inc. Organigram engaged EY for financial and tax advisory work, BMO Capital Markets for the fairness opinion, Hogan Lovells LLP as German legal counsel, and Goodmans LLP as Canadian legal counsel. Sanity Group engaged Rothschild as its exclusive financial advisor, with Katharina Erbe (RSR) and Patrick Biagosch (Biagosch Partner) as German legal counsel and McMillan LLP as Canadian legal counsel. BAT engaged Stikeman Elliott LLP as its Canadian legal counsel. Closing is anticipated in the second quarter of 2026, subject to shareholder approval, TSX approval, and German foreign direct investment clearance.